Mini-Hyper-CVD + fractionated Inotuzumab → Blinatumomab (MD Anderson post-2017 amendment) Protocol

Curated Five Minute Hematology reference for Mini-Hyper-CVD + fractionated Inotuzumab → Blinatumomab (MD Anderson post-2017 amendment). Open the approved protocol in 5MH Tools.

Acute Lymphoblastic Leukemia Adaptive treatment regimen

Open protocol

Continue to the reviewed 5MH Tools protocol reference for regimen details, schedule, supportive-care context, evidence and source transparency.

Protocol reference Mini-Hyper-CVD + fractionated Inotuzumab → Blinatumomab (MD Anderson post-2017 amendment) · Acute Lymphoblastic Leukemia · Adaptive treatment regimen · v1.2.3
Aliases mini-Hyper-CVD InO blina, mini hyper cvd inotuzumab blinatumomab
Medical review Reviewed 2026-10-07 · Duration follows the regimen-specific treatment strategy
Protocol type Treatment regimen that changes according to response, toxicity, or protocol-defined rules.
Source transparency Evidence references are available in the approved 5MH protocol.